Abstract
Serum levels of somatostatin were determined by RIA method in 50 patients with liver cirrhosis, 15 with pernicious anemia and atrophic gastritis, 31 with inflamatory bowel disease, 32 with colorectal tumors and in 40 control persons. In patients with liver cirrhosis somatostatin levels were significantly higher than in control group (p<0.01). Patients with pernicious anemia and ulcerative colitis in acute phase of the disease had significantly lower levels of somatostatin (p<0.01) (p<0.005). In patients with colorectal tumors somatostatin were significantly lower then in control group (p<0.01). Our results show that the liver is involved in somatostatin metabolism. Atrophic gastritis, ulcerative colitis and M. Crohn, so as colorectal neoplasia were associated with significantly changes in somatostatin levels which suggest the potential pathophysiologic and terapeutic role of somatostatin in those disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
